This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Luganini, A. Articles by Gribaudo, G. Search for Related Content PubMed PubMed Citation Articles by Luganini, A. Articles by Gribaudo, G.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2008, p. 1111-1120, Vol. 52, No. 3
0066-4804/08/$08.00+0     doi:10.1128/AAC.00987-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Phosphorothioate-Modified Oligodeoxynucleotides Inhibit Human Cytomegalovirus Replication by Blocking Virus Entry

Anna Luganini, Patrizia Caposio, Santo Landolfo, and Giorgio Gribaudo^*

Department of Public Health and Microbiology, University of Turin, Turin, Italy

Received 30 July 2007/ Returned for modification 14 September 2007/ Accepted 22 December 2007

Studies in animal models have provided evidence that Toll-like receptor 9 (TLR9) agonists, such as synthetic oligodeoxynucleotides (ODNs) that contain immunostimulatory deoxycytidyl-deoxyguanosine (CpG) motifs (CpG ODNs), protect against a wide range of viral pathogens. This antiviral activity has been suggested to be indirect and secondary to CpG-induced cytokines and inflammatory responses triggered through TLR9 activation. However, few studies have addressed the potential of CpG ODNs as direct antiviral agents. Here, we report on the ability of some CpG ODNs to directly suppress, almost completely, human cytomegalovirus (HCMV) replication in both primary fibroblasts and endothelial cells. Murine CMV replication was inhibited as well, whereas no inhibition was observed for herpes simplex virus type 1, adenovirus, or vesicular stomatitis virus. The antiviral activity of these ODNs was significantly reduced when they were added after virus adsorption, indicating that their action may be primarily targeted to the very early phases of the HCMV cycle. In fact, the B-class prototype CpG ODN 2006 effectively prevented the nuclear localization of pp65 and input viral DNA, which suggests that it inhibits HCMV entry. Moreover, a CpG 2006 control, ODN 2137 without CpG motifs, also showed a potent inhibitory activity on the HCMV entry phase, indicating that the anticytomegaloviral activity is independent of the CpG motif. In contrast, a phosphodiester version of CpG 2006 showed reduced antiviral activity, indicating that the inhibitory activity is dependent on the phosphorothioate backbone of the ODN. These results suggest that this yet-unrecognized activity of CpG ODNs may be of interest in the development of novel anticytomegaloviral molecules.

---

* Corresponding author. Mailing address: Department of Public Health and Microbiology, Via Santena, 9-10126 Turin, Italy. Phone: 39-011-6705633. Fax: 39-011-6705648. E-mail: giorgio.gribaudo{at}unito.it

Published ahead of print on 7 January 2008.

---

Antimicrobial Agents and Chemotherapy, March 2008, p. 1111-1120, Vol. 52, No. 3
0066-4804/08/$08.00+0     doi:10.1128/AAC.00987-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

This article has been cited by other articles:

• Chiron, D., Pellat-Deceunynck, C., Maillasson, M., Bataille, R., Jego, G. (2009). Phosphorothioate-Modified TLR9 Ligands Protect Cancer Cells against TRAIL-Induced Apoptosis. J. Immunol. 183: 4371-4377 [Abstract] [Full Text]  
• Iversen, A.-C., Steinkjer, B., Nilsen, N., Bohnhorst, J., Moen, S. H., Vik, R., Stephens, P., Thomas, D. W., Benedict, C. A., Espevik, T. (2009). A Proviral Role for CpG in Cytomegalovirus Infection. J. Immunol. 182: 5672-5681 [Abstract] [Full Text]